Nucleation of drug delivery balloons to provide improved crystal size and density
Drug delivery balloons have densely packed crystals of small particle size of the drug thereon. An amorphous drug coating is applied to a balloon surface and annealed to provide the crystals. The balloon surface is nucleated to induce formation of drug crystals in the annealing step to provide the crystals in high density with small size.
1. A method of making a drug delivery balloon having a coating thereon comprising a drug, the balloon made of a balloon material, the drug selected from the group consisting of paclitaxel, paclitaxel analogs and paclitaxel derivatives,
wherein the drug has a characteristic amorphous form and a crystalline form comprising:
a) applying a coating of the drug in the amorphous form to the balloon material, and, subsequent to applying the coating,
b) annealing with a solvent vapor the coating which has been applied in step a), the solvent vapor comprising an alcohol, to produce the crystalline form of the drug on the balloon,
wherein in the applying step a) the drug coating is applied to a balloon surface that has been nucleated by blooming of a component in the balloon material to the surface thereof, the component crystallizing at the surface of the balloon material as a result of the blooming to induce formation of drug crystals in the annealing step.
2. A method as in claim 1 wherein the coated balloon is annealed in step b) with a solvent vapor.
3. A method as in claim 2 wherein the solvent vapor comprises an alcohol and water.
4. A method as in claim 1 wherein said blooming is facilitated by a pretreatment of the balloon surface prior to applying the drug coating.
5. A method as in claim 4 wherein said pretreatment comprises a solvent vapor annealing of the balloon.
6. A method as in claim 1 wherein the balloon material comprises a polyamide block copolymer.
7. A method as in claim 1 wherein the drug is applied to the device as a formulation with an excipient.
8. Method as in claim 7 wherein said excipient is a member of the group consisting of water soluble polymers, sugars, contrast agents, citrate esters, glycerol esters of short chain monocarboxylic acids and pharmaceutically acceptable salts.
9. A method as in claim 2 wherein in the annealing step the balloon is placed in an annealing chamber in which the solvent vapor, at the time the balloon is put into the chamber, is at a vapor pressure that is less than saturation at the temperature and pressure of the chamber.
10. A method as in claim 2 wherein the in the annealing step the solvent vapor is provided in an annealing chamber having a chamber volume to solvent surface ratio in the range of from about 35-75 ml/cm 2 .
11. A method as in claim 1 wherein the balloon surface is nucleated with particulate nucleating agent on the surface of the balloon, said particulate nucleating agent having a major dimension in the size range of from about 10 nm to about 20 μm.
12. A method as in claim 11 wherein the particulate nucleating agent has a density on the balloon of from about 10 particle/mm 2 to about 5000 particles/mm 2 .
13. A method as in claim 11 wherein the particulate nucleating agent has a density on the balloon of from about 100 particles/mm 2 to about 2000 particles/mm 2 .
14. A method as in claim 1 wherein the drug is paclitaxel.
15. A method as in any one of claims 1 - 3 and 4 - 6 wherein the drug is applied to the device as a formulation without an excipient.
16. A method as in claim 1 wherein in the applying step
a) the nucleation of the balloon surface provides a controlled distribution of drug crystals in the annealing step.
17. A method of making a drug delivery balloon having a coating thereon comprising a drug, the balloon made of a balloon material, the drug selected from the group consisting of paclitaxel, paclitaxel analogs and paclitaxel derivatives, wherein the drug has a characteristic amorphous form and a crystalline form comprising:
a) applying a coating of the drug in the amorphous form to the balloon material, and, subsequent to applying the coating,
b) annealing with a solvent vapor the coating which has been applied in step a), the solvent vapor comprising an alcohol, to produce the crystalline form of the drug on the balloon,
wherein in the applying step the drug coating is applied to a balloon surface that has been nucleated by treating the balloon material so as to cause a component from within the balloon material to migrate to the surface of the balloon material, the component crystallizing at the surface of the balloon material and inducing formation of drug crystals in the annealing step.